All In Biotech

Drug Trial Radar · NCT05355935

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

A Two-part, Phase I, Double-blind, Placebo- and Positive-controlled Crossover Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Apr 27, 2022

Primary completion

Oct 7, 2022

Study completion Oct 7, 2022

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
May 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study has 2 Parts: The primary purpose of Part 1 is to determine the supratherapeutic dose of brensocatib to be used in Part 2 of the study. The primary purpose of Part 2 is to assess brensocatib's potential for prolonging the QT interval.

Conditions

  • Healthy Volunteer

Interventions

  • BrensocatibDrug

    Oral tablet.

  • MoxifloxacinDrug

    Oral tablet.

  • PlaceboDrug

    Oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants who Experienced at least one Treatment-Emergent Adverse Event (TEAE) as Assessed by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)Time frame: Up to Day 7
  2. Part 2: Placebo- and Baseline-Corrected QTcF (ΔΔQTcF)Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • USA001

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.